Presented for research literature review only Mak OT et al
While Retatrutide addresses appetite regulation and metabolic signaling, CJC-1295 works through different biological pathways that may complement GLP-1 therapy
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
FIGURE 6 Although in vitro experiment indicated TMZ showed exacerbate effect on UA induced cardiomyocytic injury, the in vivo experiment showed an opposite tendency
Buy BPC-157 (500mcg) / TB-500 (500mcg) Capsules Now